Pulmatrix (PULM) Other Non-Current Liabilities (2014 - 2025)
Pulmatrix (PULM) posted Other Non-Current Liabilities of $1000.0 for Q1 2025, down 98.51% sequentially from $67000.0 in Q4 2024.
Pulmatrix (PULM) Other Non-Current Liabilities (2014 - 2025) Analysis & Trends
Pulmatrix has reported Other Non-Current Liabilities for 6 years, with the latest figure at $1000.0 in Q1 2025.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $1000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $1000.0 (changed N/A YoY) and the FY2024 annual result came in at $67000.0, changed N/A from the prior year.
- Other Non-Current Liabilities slipped to $1000.0 in Q1 2025 per PULM's latest filing, from $67000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $67000.0 in Q4 2024 and troughed at $1000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Pulmatrix | 5.46 Mn | 5.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 1,000.00 |
| Dec 31, 2024 | 67,000.00 |
| Dec 31, 2017 | 1,000.00 |
| Sep 30, 2017 | 35,000.00 |
| Jun 30, 2017 | 35,000.00 |
| Mar 31, 2017 | 35,000.00 |
| Dec 31, 2016 | 35,000.00 |
| Sep 30, 2016 | 11,000.00 |
| Jun 30, 2016 | 11,000.00 |
| Mar 31, 2016 | 11,000.00 |
| Dec 31, 2015 | 11,000.00 |
| Sep 30, 2015 | 11,000.00 |
| Jun 30, 2015 | 11,000.00 |
| Dec 31, 2014 | 1.31 Mn |